Title
Evaluation of Phenotyping and Genotyping Characteristic of Shigella sonnei after Biofield Treatment

Permalink
https://escholarship.org/uc/item/5vj870sz

Journal
Journal of Biotechnology & Biomaterials, 05(03)

ISSN
2155-952X

Authors
Trivedi, Mahendra Kumar
Trivedi Global Inc.

Publication Date
2015-09-01

DOI
10.4172/2155-952X.1000196

Peer reviewed
Evaluation of Phenotyping and Genotyping Characteristic of Shigella sonnei after Biofield Treatment

Mahendra Kumar Trivedi1, Shrikant Patil1, Harish Shettigar1, Khemraj Bairwa2 and Snehasis Jana2,*

1Trivedi Global Inc., 10624 S Eastern Avenue Suite A-969, Henderson, NV 89052, USA
2Trivedi Science Research Laboratory Pvt. Ltd., Hall-A, Chinar Mega Mall, Chinar Fortune City, Hoshangabad Rd., Bhopal-462026, Madhya Pradesh, India

Abstract

Shigella sonnei (S. sonnei) is a non-motile, rod shape, clinically significant, Gram-negative bacterium. It is commonly associated with dysentery (shigellosis). Recently, resistance to third and fourth generation cephalosporins and fluoroquinolones has been reported in S. sonnei. In the present study, we assessed the effect of biofield treatment on phenotyping and genotyping characteristic of S. sonnei (ATCC 9290). The lyophilized samples of S. sonnei were divided in three groups (G): G-I (control, revived), G-II (treatment, revived), and G-III (treatment, lyophilized). All these groups (control and biofield treated) were analyzed against antimicrobial susceptibility, biochemical reactions, and biotype number. The 16S rDNA sequencing was carried out to establish the phylogenetic relationship of S. sonnei with different bacterial species. The treated cells of S. sonnei exhibited an alteration of 3.33%, 10%, and 23.33% of total 30 tested antimicrobials in susceptibility assay for G-II on day 5 and 10 and G-III on day 10, respectively as compared to control. The treated cells of S. sonnei showed a significant change of about 12.12%, 12.12%, and 57.58% biochemical reactions out of 33 tests in treated groups of G-II on day 5 and 10 and G-III on day 10, respectively. The biotype number was also changed in treated samples of S. sonnei. Based on nucleotide homology sequences and phylogenetic analysis, the nearest homolog species of S. sonnei (GenBank Accession Number: EU009190) was identified as Shigella flexneri (EF843668). These results revealed that biofield treatment can prevent the absolute resistance in microbes against the existing antimicrobials.

Keywords: Antimicrobial susceptibility; Biofield treatment; 16S rDNA gene sequencing; Shigella sonnei

Abbreviations: MIC: Minimum Inhibitory Concentration; ATCC: American Type Culture Collection; NBPC30: Negative Breakpoint Combo 30; NCBI: National Center for Biotechnology Information; WHO: World Health Organization; 16S rDNA: 16Svedberg Unit Ribosomal Deoxyribonucleic Acid; BLAST: Basic Local Alignment Search Tool; Outs: Operational Taxonomic Units

Introduction

Development of antimicrobial resistance in several microbes like bacteria, viruses, fungi, or in parasites has been reported globally in the recent few decades. Frequent and improper use of antimicrobial further accelerated the incidence of microbial resistance [1]. Shigella sonnei (S. sonnei) is a rod shape, non-motile, facultative anaerobic Gram-negative and lactose-fermenting bacterium. S. sonnei is associated with gastrointestinal tract (GIT) infection disease shigellosis in both developed and developing countries, where the sanitation is insufficient [2,3]. S. sonnei is usually transmitted by fecal-oral route, direct interpersonal contact, contaminated food, water, or uncooked food. Shigella infection is the third most common gastroenteritis after Salmonella and Campylobacter infection in the USA. Recently, S. sonnei has become the most prevalent species in the developed world. It is estimated to cause 80–165 million cases of disease and 600,000 deaths annually, worldwide [4]. The S. sonnei has been acquired resistant to commonly used antimicrobials like streptomycin, tetracycline, sulfonamide, trimethoprim, and ampicillin. Emergence of extended-spectrum β-lactamas (ESBLs) in S. sonnei was also detected in Korea [2,5]. Therefore the multidrug therapy required to treat the infection cause by resistant strain of microbes. However, multiple drug therapy shows serious toxicity and associated adverse effects like neurotoxicity and nephrotoxicity [6]. Due to associated side effects and failure of drug therapy, an alternate treatment approach is required. Recently, an alternate treatment known as biofield energy is reported that inhibits the growth of bacterial cultures [7]. Biofield is an electromagnetic field that permeates and surrounds living organisms and referred as biologically produced electromagnetic field and subtle energy field that provides regulatory and communication functions within the human organism [8]. Various internal physiological processes such as blood flow, brain and heart function etc. generates biofield. Researchers have attempted different biologic studies and effects of biofield on various biomolecules such as proteins, antibiotics [9], conformational change in DNA [10] etc. Thus, human has the ability to harness the energy from environment or universe and can transmit into any living or nonliving object(s) around the Globe. The objects always receive the energy and responding into useful way that is called biofield energy and the process is known as biofield treatment [11]. Mr. Mahendra Trivedi's biofield treatment (The Trivedi Effect) has renowned to alter the various physicochemical characteristics of metals and ceramics [11-17]. Quality and quantity of several agriculture products have been improved by several folds in the biofield treated plants [18-20] and growth and adaptation of the plant were also enhanced with the help of biofield treatment [21,22]. In addition, the biofield treatment has considerably altered the phenotype and biotype of the microbe and subsequently, the susceptibility to antimicrobials was also changed [23-25].

*Corresponding author: Snehasis Jana, Trivedi Science Research Laboratory Pvt. Ltd., Hall-A, Chinar Mega Mall, Chinar Fortune City, Hoshangabad Rd., Bhopal-462026, Madhya Pradesh, India, Tel: +91-755-6660006; E-mail: publication@trivediarm.com

Received August 05, 2015; Accepted August 25, 2015; Published September 01, 2015

Citation: Trivedi MK, Patil S, Shettigar H, Bainwa K, Jana S (2015) Evaluation of Phenotyping and Genotyping Characteristic of Shigella sonnei after Biofield Treatment. J Biotechnol Biomater 5: 196. doi:10.4172/2155-952X.1000196

Copyright: © 2015 Trivedi MK, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Based on the knowledge of existing literatures and considering the clinical significance of *S. sonnei*, we evaluated to see the impact of biofield treatment on antimicrobial susceptibility, biochemical reactions pattern, biotype number, and 16S rDNA gene sequencing of the microbe.

**Materials and Methods**

Two lyophilized vials of *S. sonnei* [American Type Culture Collection (ATCC) 9290] were purchased from MicroBioLogics, Inc., USA. The microbial sample vials were stored as per the suggested storage conditions until further use. The antimicrobial susceptibility study, biochemical reactions pattern, and biotype number were evaluated by MicroScan Walk-Away® (Dade Behring Inc., West Sacramento, CA) through Negative Breakpoint Combo 30 (NBPC30) panel. The 16S rDNA sequencing was performed using Ultrapure Genomic DNA Prep Kit (Cat KT 83, Bangalore Genei, India).

**Biofield treatment**

The lyophilized strain of *S. sonnei* were divided into three groups (G) like G-I (control), G-II (treatment, revived), and G-III (treatment, lyophilized). G-I consider as control. No treatment was given. The treatment groups (II and III) were in sealed pack and handed over to Mr. Trivedi for biofield treatment under laboratory condition. Mr. Trivedi provided the treatment through his energy transmission process to the treated groups without touching the samples. Subsequently, group G-I and G-II were assessed on day 5 and 10; and G-III was assessed on day 10. After that, all groups were evaluated for an antimicrobial susceptibility, biochemical reactions pattern, and biotype number [25]. The 16S rDNA gene sequencing of *S. sonnei* was also carried out.

**Investigation of antimicrobial susceptibility of *S. sonnei***

The antimicrobial susceptibility of *S. sonnei* was evaluated with the help of automated instrument, MicroScan Walk-Away using Negative Breakpoint Combo 30 (NBPC30) panel as per the manufacturers instructions [26]. The minimum inhibitory concentration (MIC) and a qualitative susceptibility like resistant (R), intermediate (I), and susceptible (S) were determined by analyzing the lowest antimicrobial concentration showing microbial growth inhibition [25]. The antimicrobial sensitivity study was carried out following 30 antimicrobials such as amikacin, amoxicillin/K-clavulanate acid, ampicillin/subactam, ampicillin, aztreonam, ceftazolin, cefepime, cefotaxime, cefotetan, cefoxitin, ceftriaxone, cefuroxime, cephalothin, chloramphenicol, ciprofloxacin, gatifloxacin, gentamicin, imipenem, levofloxacin, meropenem, moxifloxacin, nitrofurantoin, norfloxacin, piperacillin, tazobactam, tetracycline, ticarcillin, tobramycin, and trimethoprim/sulfamethoxazole. All these antimicrobials were procured from Sigma-Aldrich.

**Results**

The antimicrobial sensitivity data were reported in Table 1 and 2. The result showed that the biofield treated *S. sonnei* exhibited a significant alteration in susceptibility assay of about 3.33% (G-II on day 5), 10% (G-II on day 10), and 23.33% (G-III on day 10) of total tested antimicrobials. The antimicrobials ampicillin, aztreonam, cefotaxime, cefazidime, chloramphenicol, and tetracycline were converted from R → S; simultaneously more than 2 folds decreases in MIC values in lyophilized treated group G-III; cefotaxime showed a decrease in susceptibility from R → I in G-II on day 10. Besides, amoxicillin/K-clavulanate and ampicillin/subactam were converted from S → R in G-II and cefepime converted from I → S in G-III on day 10.

**Identification of *S. sonnei* by biochemical reactions**

The results of biochemical reactions of *S. sonnei* are presented in Table 3, which represent a significant alteration in biochemical reactions of about 12.12% (G-II on day 5 and 10), and 57.58% (G-III on day 10) of total tested biochemicals as compared to control. The biochemicals such as adonitol, cephaloholin, citrate, colistin, esculin hydrolysis, hydrogen sulfide, indole, inositol, kanamycin, lysine, malonate, melibiose, nitrate, oxidation-fermentation, galactosidase, ornithine, oxidase, penicillin, raffinose, rhhamnose, sorbitol, sucrose, tartrate, tryptophan deaminase, tobramycin, urea, and Voges-Proskauer. All these biochemicals were procured from Sigma-Aldrich.

**Biochemical studies**

The biochemical reactions of *S. sonnei* were carried out using MicroScan Walk-Away® system where, interpretation of biochemical reactions for microbial identification of Gram-negative organisms resulted in high accuracy [27,28]. The biochemical reactions patterns of control and treated samples of *S. sonnei* were performed using the following 33 biochemicals such as acetamide, adonitol, arabinox, arginine, cetrimide, cephalothin, citrate, colistin, esculin hydrolysis, nitrofurantoin, glucose, hydrogen sulfide, indole, inositol, kanamycin, lysine, malonate, melibiose, nitrate, oxidation-fermentation, galactosidase, ornithine, oxidase, penicillin, raffinose, rhhamnose, sorbitol, sucrose, tartrate, tryptophan deaminase, tobramycin, urea, and Voges-Proskauer were changed from positive (control) → negative reactions (treated) in G-III microbes. Additionally, arginine was converted from positive to negative reaction in entire treated groups. Nitrofurantoin was converted from positive to negative in G-II on day 5 and G-III on day 10 (Table 3). Tartrate was converted from positive to negative reaction in both G-II and G-III on day 10; and inositol and tryptophan deaminase were converted from negative to positive reaction in G-II on both days (Table 3). All the data were compared as controlled to control.
Effect of biofield treatment on biotype number

Biotype number of *S. sonnie* was determined on MicroScan Walk-Away® processed panel. The result was demonstrated an alteration in biotype number of *S. sonnie* in the entire treated groups G-II and G-III (Table 4). However, the species (*S. sonnie*) was remained unchanged in the entire treated group.

16S rDNA gene sequencing

The 16S rDNA sequence was determined in *S. sonnie* and shown in Figure 1. The alignment and comparison of the gene sequences were performed with the sequences stored in Gene Bank data base available from NCBI using the algorithm BLASTn program. As evidenced from nucleotides homology and phylogenetic analysis the sample 6A (*S. sonnie*) was identified as the same species (*S. sonnie*) with 99% identity of gene sequencing data. Ten bacterial species and *S. sonnie* were considered as Operational Taxonomic Units (OTUs) to facilitate the investigation of phylogenetic relationship of *S. sonnie* among other related species. Total 1500 base nucleotide of 16S rDNA gene sequences were compared by multiple alignments with the help of ClustalW in MEGA3.1 [30], and the data are shown in Table 5.

Table 1: Effect of biofield treatment on *Shigella sonnie* to antimicrobial susceptibility pattern of selected antimicrobials

| S. No. | Antimicrobial | Control G-I | Treated G-II | Treated G-III |
|--------|---------------|-------------|--------------|--------------|
| 1      | Amikacin      | R           | R            | R            |
| 2      | Amoxicillin/k-clavulanate | S | S | R | S |
| 3      | Ampicillin/sublactam | S | I | R | S |
| 4      | Ampicillin    | R           | R            | R            |
| 5      | Aztreonam     | R           | R            | R            |
| 6      | Cefazolin     | I           | I            | I            |
| 7      | Cefepime      | I           | I            | I            |
| 8      | Cefotaxime    | R           | R            | I            |
| 9      | Cefotetan     | R           | R            | R            |
| 10     | Cefoxitin     | R           | R            | R            |
| 11     | Ceftazidime   | R           | R            | S            |
| 12     | Ceftriaxone   | S           | S            | S            |
| 13     | Cefuroxime    | R           | R            | R            |
| 14     | Cephalothin   | R           | R            | R            |
| 15     | Chloramphenicol | R       | R            | S            |
| 16     | Ciprofloxacin | S           | S            | S            |
| 17     | Gatifloxacin  | S           | S            | S            |
| 18     | Gentamicin    | I           | I            | I            |
| 19     | Imipenem      | S           | S            | S            |
| 20     | Levofloxacin  | S           | S            | S            |
| 21     | Meropenem     | S           | S            | S            |
| 22     | Moxifloxacin  | S           | S            | S            |
| 23     | Nitrofurantoine | R          | R            | S            |
| 24     | Norfloxacin   | S           | S            | S            |
| 25     | Piperacillin  | S           | S            | S            |
| 26     | Piperacillin/tazobactam | S | S | S | S |
| 27     | Tetracycline  | R           | R            | R            |
| 28     | Ticarcillin/k-clavulanate | S | S | S | S |
| 29     | Tobramycin    | R           | R            | R            |
| 30     | Trimethoprim/sulfamethoxazole | S | S | S | S |

Table 2: Effect of biofield treatment on *Shigella sonnie* to minimum inhibitory concentration (MIC) of selected antimicrobials

| S. No. | Antimicrobial | Control G-I | Treated G-II | Treated G-III |
|--------|---------------|-------------|--------------|--------------|
| 1      | Amikacin      | S>32        | >32          | >32          | >32          |
| 2      | Amoxicillin/k-clavulanate | ≤8/4       | ≤8/4         | >16/8        | ≤8/4         |
| 3      | Ampicillin/sublactam | ≤8/4       | ≤8/4         | 16/8         | ≤8/4         |
| 4      | Ampicillin    | >16         | >16          | >16          | ≤8           |
| 5      | Aztreonam     | >16         | >16          | >16          | ≤8           |
| 6      | Cefazolin     | 16          | 16           | 16           | 16           |
| 7      | Cefepime      | 16          | 16           | 16           | 16           |
| 8      | Cefotaxime    | >32         | 32           | 32           | ≤6           |
| 9      | Cefotetan     | >32         | 32           | >32          | ≤6           |
| 10     | Cefoxitin     | >16         | >16          | >16          | >16          |
| 11     | Ceftazidime   | >16         | >16          | >16          | ≤8           |
| 12     | Ceftriaxone   | ≤8          | ≤8           | ≤8           | ≤8           |
| 13     | Cefuroxime    | >16         | >16          | >16          | >16          |
| 14     | Cephalothin   | 16          | 16           | 16           | 16           |
| 15     | Chloramphenicol | >16         | >16          | >16          | ≤8           |
| 16     | Ciprofloxacin | ≤1          | ≤1           | ≤1           | ≤1           |
| 17     | Gatifloxacin  | ≤2          | ≤2           | ≤2           | ≤2           |
| 18     | Gentamicin    | >8          | >8           | >8           | >8           |
| 19     | Imipenem      | ≤4          | ≤4           | ≤4           | ≤4           |
| 20     | Levofloxacin  | ≤2          | ≤2           | ≤2           | ≤2           |
| 21     | Meropenem     | ≤4          | ≤4           | ≤4           | ≤4           |
| 22     | Moxifloxacin  | ≤2          | ≤2           | ≤2           | ≤2           |
| 23     | Nitrofurantoine | >64         | >64          | >64          | >64          |
| 24     | Norfloxacin   | ≤4          | ≤4           | ≤4           | ≤4           |
| 25     | Piperacillin  | ≤16         | ≤16          | ≤16          | ≤16          |
| 26     | Piperacillin/tazobactam | ≤16       | ≤16          | ≤16          | ≤16          |
| 27     | Tetracycline  | >8          | >8           | >8           | ≤4           |
| 28     | Ticarcillin/k-clavulanate | ≤16       | ≤16          | ≤16          | ≤16          |
| 29     | Tobramycin    | >8          | >8           | >8           | >8           |
| 30     | Trimethoprim/sulfamethoxazole | ≤2/38       | ≤2/38        | ≤2/38        | ≤2/38        |

G, stands for group; MIC data is presented in µg/mL

Figure 1: Phylogenetic tree of the partial 16S rDNA gene sequencing using MEGA 3.1 software by Neighbor joining method.

As evidenced from Table 6, the lowest value of genetic distance from *S. sonnie* was 0.002 base substitutions per site. The nearest homolog genus-species of *S. sonnie* (Genbank accession number: EU009190) was determined by analyzing the 16S rDNA sequencing and phylogenetic tree, and found to be *Shigella flexneri* (Genbank EU009190).
Microbial infections that have been curable for decades. Microbes naturally mutate in a post-antibiotic era, where people will die from simple microbial infections. Antimicrobial resistance is a major global threat to public health, that biofield treatment can alter the sensitivity of antimicrobials against Shigella sonnei sample 6A was identified as Shigella boydii. It seems that biofield treatment can play a potential role to interact with biofield treatment. The present study revealed that biofield treatment has significantly altered the sensitivity of microbes in both control and treated groups of Shigella sonnei. Based on the BLASTn analysis, the closest homologues species of Shigella sonnei from sequence alignment using NCBI GenBank and Ribosomal database project (RDP).

Due to increasing the number of clinical specimens, cost-effectiveness, and convenient interfaces with hospital information systems and laboratory use of automated or semi-automated systems for the susceptibility testing and identification of microbes has been increased recently [32]. Therefore, we also utilized the Microscan WalkAway system for analysis of antimicrobial sensitivity, biochemical reactions, and biotyping. The overall result of antimicrobial susceptibility of biofield treated S. sonnei suggested that biofield treatment has significantly altered the sensitivity of microbes in both side (either S → R or R → S) as compared to control. The biochemical reactions of treated cells of S. sonnei were altered in the range of 12.11 to 57.58% in treated group as compared to control, which could be due to some alteration happened in metabolic enzyme systems and/or genetic systems. It was also found that there was an alteration of biotype number in treated groups of S. sonnei. Based on the BLASTn analysis, the sample 6A was identified as S. sonnei. The closest homologues species of S. sonnei was identified as Shigella flexneri. The present study revealed that biofield treatment can alter the sensitivity of antimicrobials against S. sonnei. It seems that biofield treatment can play a potential role to circumvent the severe microbial infection in the fast and cost effective way as compared to modern medication.

**Conclusion**

Altogether data suggest that there was an impact of biofield treatment on antimicrobial susceptibility, biochemical reactions pattern, and biotype number of S. sonnei. To the best of our knowledge, this is the first report describing the significant impact of biofield treatment on S. sonnei in relation to change the sensitivity of antimicrobials.
16. Trivedi MK, Patil S, Tallapragada RM (2013) Effect of bio field treatment on the physical and thermal characteristics of silicon, tin and lead powders. J Material Sci Eng 2: 125.

17. Trivedi MK, Patil S, Tallapragada RMR (2015) Effect of biofield treatment on the physical and thermal characteristics of aluminium powders. Ind Eng Manage 4: 151.

18. Shinde V, Sances F, Patil S, Spence A (2012) Impact of Biofield treatment on growth and yield of lettuce and tomato. Aust J Basic Appl Sci 6: 100-105.

19. Sances F, Flora E, Patil S, Spence A, Shinde V (2013) Impact of biofield treatment on ginseng and organic blueberry yield. Agrivita J Agric Sci 35.

20. Lensen AW (2013) Biofield and fungicide seed treatment influences on soybean productivity, seed quality and weed community. Agriculture Journal 8: 138-143.

21. Patil SA, Nayak GB, Barve SS, Tembe RP, Khan RR (2012) Impact of biofield treatment on growth and anatomical characteristics of Pogostemon cablin (Benth.). Biotechnology 11: 154-162.

22. Nayak G, Allekar N (2015) Effect of biofield treatment on plant growth and adaptation. J Environ Health Sci 1: 1-9.

23. Trivedi MK, Patil S (2008) Impact of an external energy on Staphylococcus epidermidis [ATCC-13518] in relation to antibiotic susceptibility and biochemical reactions-an experimental study. J Accord Integ Med 4: 230-235.

24. Trivedi MK, Patil S (2008) Impact of an external energy on Yersinia enterocolitica [ATCC-23715] in relation to antibiotic susceptibility and biochemical reactions: an experimental study. Internet J Alternat Med 6.

25. Trivedi MK, Patil S, Shettigar H, Gangwar M, Jana S (2015) Antimicrobial sensitivity pattern of Pseudomonas fluorescens after biofield treatment. J Infect Dis Ther 3: 222.

26. Fader RC, Weaver E, Fossetti R, Toyras M, Vanderlaan J, et al. (2013) Multilaboratory study of the biometric automated well-reading instrument versus MicroScan WalkAway for reading MicroScan antimicrobial Susceptibility and identification panels. J Clin Microbiol 51: 1548-1554.

27. Gomaa FM, Tawakol WM, Abo El-Azm FI (2014) Phenotypic and genotypic detection of some antimicrobial resistance mechanisms among multidrug-resistant Acinetobacter baumannii isolated from immunocompromised patients in Egypt. Egypt J Med Microbiol 23: 99-111.

28. Jorgensen JH, Ferraro MJ (2009) Antimicrobial susceptibility testing: a review of general principles and contemporary practices. Clin Infect Dis 49: 1749-1755.

29. Lennox VA, Ackerman VP (1984) Biochemical identification of bacteria by replicator methods on agar plates. Pathology 16: 434-440.

30. Kumar S, Tamura K, Nei M (2004) MEGA3: Integrated software for Molecular Evolutionary Genetics Analysis and sequence alignment. Brief Bioinform 5: 150-163.

31. Cohen ML (1992) Epidemiology of drug resistance: implications for a post-antimicrobial era. Science 257: 1050-1055.

32. Sader HS, Fritsche TR, Jones RN (2006) Accuracy of three automated systems (MicroScan WalkAway, VITEK, and VITEK 2) for susceptibility testing of Pseudomonas aeruginosa against five broad-spectrum beta-lactam agents. J Clin Microbiol 44: 1101-1104.